Plasma chemokines as immune biomarkers for diagnosis of pediatric tuberculosis.
Biomarkers
Chemokines
Pediatric tuberculosis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
11 Oct 2021
11 Oct 2021
Historique:
received:
16
04
2021
accepted:
10
09
2021
entrez:
12
10
2021
pubmed:
13
10
2021
medline:
14
10
2021
Statut:
epublish
Résumé
Diagnosing tuberculosis (TB) in children is challenging due to paucibacillary disease, and lack of ability for microbiologic confirmation. Hence, we measured the plasma chemokines as biomarkers for diagnosis of pediatric tuberculosis. We conducted a prospective case control study using children with confirmed, unconfirmed and unlikely TB. Multiplex assay was performed to examine the plasma CC and CXC levels of chemokines. Baseline levels of CCL1, CCL3, CXCL1, CXCL2 and CXCL10 were significantly higher in active TB (confirmed TB and unconfirmed TB) in comparison to unlikely TB children. Receiver operating characteristics curve analysis revealed that CCL1, CXCL1 and CXCL10 could act as biomarkers distinguishing confirmed or unconfirmed TB from unlikely TB with the sensitivity and specificity of more than 80%. In addition, combiROC exhibited more than 90% sensitivity and specificity in distinguishing confirmed and unconfirmed TB from unlikely TB. Finally, classification and regression tree models also offered more than 90% sensitivity and specificity for CCL1 with a cutoff value of 28 pg/ml, which clearly classify active TB from unlikely TB. The levels of CCL1, CXCL1, CXCL2 and CXCL10 exhibited a significant reduction following anti-TB treatment. Thus, a baseline chemokine signature of CCL1/CXCL1/CXCL10 could serve as an accurate biomarker for the diagnosis of pediatric tuberculosis.
Sections du résumé
BACKGROUND
BACKGROUND
Diagnosing tuberculosis (TB) in children is challenging due to paucibacillary disease, and lack of ability for microbiologic confirmation. Hence, we measured the plasma chemokines as biomarkers for diagnosis of pediatric tuberculosis.
METHODS
METHODS
We conducted a prospective case control study using children with confirmed, unconfirmed and unlikely TB. Multiplex assay was performed to examine the plasma CC and CXC levels of chemokines.
RESULTS
RESULTS
Baseline levels of CCL1, CCL3, CXCL1, CXCL2 and CXCL10 were significantly higher in active TB (confirmed TB and unconfirmed TB) in comparison to unlikely TB children. Receiver operating characteristics curve analysis revealed that CCL1, CXCL1 and CXCL10 could act as biomarkers distinguishing confirmed or unconfirmed TB from unlikely TB with the sensitivity and specificity of more than 80%. In addition, combiROC exhibited more than 90% sensitivity and specificity in distinguishing confirmed and unconfirmed TB from unlikely TB. Finally, classification and regression tree models also offered more than 90% sensitivity and specificity for CCL1 with a cutoff value of 28 pg/ml, which clearly classify active TB from unlikely TB. The levels of CCL1, CXCL1, CXCL2 and CXCL10 exhibited a significant reduction following anti-TB treatment.
CONCLUSION
CONCLUSIONS
Thus, a baseline chemokine signature of CCL1/CXCL1/CXCL10 could serve as an accurate biomarker for the diagnosis of pediatric tuberculosis.
Identifiants
pubmed: 34635070
doi: 10.1186/s12879-021-06749-6
pii: 10.1186/s12879-021-06749-6
pmc: PMC8504024
doi:
Substances chimiques
Biomarkers
0
Chemokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1055Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2021. The Author(s).
Références
Eur Respir J. 2008 Dec;32(6):1607-15
pubmed: 18684849
Front Immunol. 2021 Apr 16;12:653898
pubmed: 33936077
Sci Rep. 2017 Mar 30;7:45477
pubmed: 28358118
PLoS One. 2012;7(9):e46041
pubmed: 23029377
Lancet Infect Dis. 2014 Oct;14(10):931-8
pubmed: 25185458
J Infect. 2014 Jan;68(1):62-70
pubmed: 23954615
N Engl J Med. 2012 Jul 26;367(4):348-61
pubmed: 22830465
Clin Vaccine Immunol. 2011 Nov;18(11):1856-64
pubmed: 21955625
Semin Immunol. 2014 Dec;26(6):552-8
pubmed: 25444549
BMC Neurol. 2019 Apr 6;19(1):56
pubmed: 30954070
Lancet Infect Dis. 2019 Mar;19(3):e96-e108
pubmed: 30322790
J Infect. 2013 Apr;66(4):357-65
pubmed: 23178506
Semin Respir Crit Care Med. 2018 Jun;39(3):271-285
pubmed: 30071543
J Infect. 2014 Dec;69(6):590-9
pubmed: 24975172
BMC Bioinformatics. 2006 Mar 09;7:123
pubmed: 16526949
Clin Infect Dis. 2004 Jan 15;38(2):199-205
pubmed: 14699451
Clin Infect Dis. 2015 Oct 15;61Suppl 3:S179-87
pubmed: 26409281
Cytokine Growth Factor Rev. 2013 Apr;24(2):105-13
pubmed: 23168132
Thorac Surg Clin. 2019 Feb;29(1):109-121
pubmed: 30454917
Front Pediatr. 2019 Sep 25;7:376
pubmed: 31612118
J Infect. 2020 Dec;81(6):873-881
pubmed: 33007340
EBioMedicine. 2020 Aug;58:102909
pubmed: 32711253
Sci Rep. 2018 Feb 8;8(1):2675
pubmed: 29422548
Lancet Infect Dis. 2013 Apr;13(4):287-9
pubmed: 23531386
Int J Tuberc Lung Dis. 2010 Dec;14(12):1548-55
pubmed: 21144239
Sci Rep. 2019 Dec 3;9(1):18217
pubmed: 31796883
Clin Microbiol Infect. 2019 Jun;25(6):667-672
pubmed: 30553864
Lancet Infect Dis. 2019 Sep;19(9):e322-e329
pubmed: 31221543